Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 2014. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility (PDMRs), or Connected Persons under the GlaxoSmithKline 2009 Performance Share Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share plan transactions.
- Share Price: 1572.00 pence per Ordinary Share; $54.40 per American Depositary Share (ADS).
- Transaction Type: Notional re-investment of dividends paid on July 10, 2014.
Material Changes
The filing details increases in notional interests for specific individuals following the dividend re-investment:
- Dr M M Slaoui: Connected person Dr K Slaoui received an increase of 71.287 ADSs.
- Mr P C Thomson: Received an increase of 75.244 Ordinary Shares.
No material changes to the company's financial position or operations are reported in this document.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a compliance notification regarding Rule 12g3-2(b) and Disclosure and Transparency Rule 3.1.4R(1)(c).
Investor Verification Points
- Verify the vesting schedule for the 2009 Performance Share Plan to understand when notional dividends become payable.
- Confirm the total shareholding positions of Dr M M Slaoui and Mr P C Thomson post-transaction.
- Review the dividend payment date of July 10, 2014, in the company's broader financial reports.